Daniel Kaemmerer
Overview
Explore the profile of Daniel Kaemmerer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frilling A, Clift A, Kaemmerer D, Steinkraus K, Schrader J, Wolter S, et al.
Ann Surg
. 2024 Dec;
PMID: 39676650
Objective: To describe the evolution of management strategies for neuroendocrine liver metastases (NE LM) and trends in patient outcomes over the preceding 3 decades. Summary Background Data: Liver metastases are...
2.
Kaemmerer D, Hommann M
Inn Med (Heidelb)
. 2024 Jul;
65(11):1147-1149.
PMID: 39019992
Life-threatening side effects of mistletoe therapy are mostly negated by physicians working in complementary medicine. This article reports on a case of life-threatening anaphylactic shock after carrying out mistletoe therapy....
3.
Beyer A, Kaemmerer D, Sanger J, Lupp A
J Histochem Cytochem
. 2024 Jun;
72(7):467-487.
PMID: 38907656
Little is known about the adaptor protein FAM159B. To determine whether FAM159B expression findings in rats or mice can be extrapolated to humans, we compared FAM159B expression in healthy tissue...
4.
Ruhnke N, Beyer A, Kaemmerer D, Sanger J, Schulz S, Lupp A
Exp Mol Pathol
. 2024 May;
137:104902.
PMID: 38788249
Objective: Little information is available concerning protein expression of the free fatty acid receptor 2 (FFAR2), especially in tumours. Therefore, the aim of the present study was to comprehensively characterise...
5.
Gerlach L, Beyer A, Kaemmerer D, Sanger J, Evert K, Schulz S, et al.
Sci Rep
. 2023 Nov;
13(1):18993.
PMID: 37923782
Little is known about the expression of the orphan G protein-coupled receptor GPR19 at the protein level. Therefore, we developed a rabbit antibody, targeting human GPR19. After verification of the...
6.
Wende B, Beyer A, Ruhnke N, Kaemmerer D, Sanger J, Schulz S, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36835377
Little information is available concerning protein expression of the calcitonin receptor-like receptor (CALCRL) at the protein level. Here, we developed a rabbit monoclonal antibody, 8H9L8, which is directed against human...
7.
Nesti C, Brautigam K, Benavent M, Bernal L, Boharoon H, Botling J, et al.
Lancet Oncol
. 2023 Jan;
24(2):187-194.
PMID: 36640790
Background: Awareness of the potential global overtreatment of patients with appendiceal neuroendocrine tumours (NETs) of 1-2 cm in size by performing oncological resections is increasing, but the rarity of this...
8.
Beyer A, Kaemmerer D, Sanger J, Lupp A
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362289
Little is known about the adaptor protein FAM159B. Recently, FAM159B was shown to be particularly expressed in neuroendocrine cells and tissues, such as pancreatic islets and neuroendocrine cells of the...
9.
Rosner E, Kaemmerer D, Sanger J, Lupp A
Transl Oncol
. 2022 Sep;
25:101526.
PMID: 36067541
Background: Targeting programmed death protein 1 (PD-1) or its ligand PD-L1 is a promising therapeutic approach for many types of cancer in which PD-L1 is overexpressed. However, data on PD-L1...
10.
Ehms B, Kaemmerer D, Sanger J, Schulz S, Lupp A
Sci Rep
. 2022 Aug;
12(1):14722.
PMID: 36042228
Somatostatin receptors SST1, SST2, and SST5 are overexpressed in neuroendocrine neoplasms (NENs), but little is known about SST4 expression in NENs because of a lack of specific monoclonal antibodies. We...